Millennium Management
CSTL icon

Millennium Management’s Castle Biosciences CSTL Stock Holding History

Millennium Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.67M Buy
353,319
+44,405
+14% +$1.45M ﹤0.01% 2311
2025
Q4 		$12M Sell
308,914
-266,175
-46% -$8.58M 0.01% 2068
2025
Q3 		$13.1M Buy
575,089
+146,692
+34% +$2.98M 0.01% 2107
2025
Q2 		$8.75M Buy
428,397
+173,648
+68% +$3.21M ﹤0.01% 2405
2025
Q1 		$5.1M Sell
254,749
-294,060
-54% -$7.28M ﹤0.01% 2843
2024
Q4 		$14.6M Buy
548,809
+408,272
+291% +$12.4M 0.01% 1796
2024
Q3 		$4.01M Buy
140,537
+105,710
+304% +$2.69M ﹤0.01% 3043
2024
Q2 		$758K Sell
34,827
-213,726
-86% -$4.76M ﹤0.01% 4312
2024
Q1 		$5.51M Sell
248,553
-467,797
-65% -$10.2M ﹤0.01% 2765
2023
Q4 		$15.5M Buy
716,350
+121,254
+20% +$2.13M 0.01% 1779
2023
Q3 		$10.1M Sell
595,096
-440,497
-43% -$7.7M 0.01% 2049
2023
Q2 		$14.2M Buy
1,035,593
+210,156
+25% +$4.26M 0.01% 1696
2023
Q1 		$18.8M Sell
825,437
-87,938
-10% -$2.15M 0.01% 1373
2022
Q4 		$21.5M Sell
913,375
-48,966
-5% -$1.14M 0.01% 1377
2022
Q3 		$25.1M Buy
962,341
+60,252
+7% +$1.69M 0.01% 1136
2022
Q2 		$19.8M Buy
902,089
+629,448
+231% +$14.6M 0.01% 1321
2022
Q1 		$12.2M Sell
272,641
-243,865
-47% -$10.1M 0.01% 1921
2021
Q4 		$22.1M Buy
516,506
+113,147
+28% +$5.91M 0.01% 1337
2021
Q3 		$26.8M Buy
+403,359
New +$28.4M 0.02% 1069
2021
Q2 		– Sell
-250,070
Closed -$17.1M – 6598
2021
Q1 		$17.1M Sell
250,070
-233,209
-48% -$17.5M 0.01% 1226
2020
Q4 		$32.5M Buy
483,279
+128,548
+36% +$6.97M 0.02% 724
2020
Q3 		$18.3K Buy
354,731
+6,803
+2% +$303K 0.02% 848
2020
Q2 		$13.1M Buy
347,928
+138,479
+66% +$4.73M 0.02% 1026
2020
Q1 		$6.24M Buy
+209,449
New +$6.32M 0.01% 1166
2019
Q4 		– Sell
-155,538
Closed -$2.81M – 4272
2019
Q3 		$2.81M Buy
+155,538
New +$3.45M ﹤0.01% 2218

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management's CSTL Position: Q1 2026 in Review

Millennium Management increased its Castle Biosciences (CSTL) stake by 14% in Q1 2026, buying an estimated $1.45M and bringing the position to 353,319 shares worth $8.67M. The position accounts for ﹤0.01% of the portfolio, ranked #2311.

Millennium Management first reported a position in CSTL in Q3 2019 and has held it in 25 quarters since. The position peaked at $32.5M in Q4 2020. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Millennium Management held 353,319 shares of Castle Biosciences worth $8.67M as of Q1 2026.
  • Millennium Management bought 44,405 Castle Biosciences shares in Q1 2026, an estimated $1.45M.
  • Castle Biosciences made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2311 holding.
  • Millennium Management first reported a position in Castle Biosciences in Q3 2019 and has held it in 25 quarters since.
  • Millennium Management's Castle Biosciences position peaked at $32.5M in Q4 2020.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.